How it works:
The funding will be spread across three Australian based projects that are focused on targeting rogue cancer cells, overcoming treatment-resistant disease, and a hormonal pill.
Why it matters:
Ovarian cancer is the deadliest gynaecological disease with more than 1,500 Australia women diagnosed with the disease each year.
It is known as the silent killer, as women in the early stages typically do not present with any symptoms meaning the disease is often not detected until the advanced stages, when it has spread beyond the ovaries.
What they’re saying:
Lucinda Nolan, OCRF Chief Executive:
“The Ovarian Cancer Research Foundation is one of the largest not-for-profit funders of ovarian cancer research in Australia. Since 2001, we have given more than $16.5 million to Australian researchers in an attempt to make serious inroads into understanding this insidious disease, developing an early detection test and finding new treatments.”
“The researchers we have funded this year are taking innovative approaches to tackling ovarian cancer from a range of different angles – targeting rogue ‘leader cells’ and proteins that allow the disease to proliferate, and potentially preventing it all together with a pill.”